

Patient Details

Forename

Surname

Address

Patient NO

Local No.

Protocol

Course Name:

Consultant

Ward

Type of line

No. of lumen:

NHS No

PALBOCICLIB

Palbociclib

Diagnosis

Carcinoma of Breast

SA (m²)

Height (m)

Weight (kg)

Page:1 of 2

Monitoring	Acceptable Range		Date Due	Date of Test	Value	Checked
Height (m)						
Weight (kg)						
SA (m²)						
ALA TRANSAM 1 ULN	0.00	40.00	Day 1			
BILIRUBIN 2 X ULN	0.00	42.00	Day 1			
NEUTROPHILS > 1.0	1.00	15.00	Day 1			
PLATELETS> 75	75.00	600.00	Day 1			

Additional Prescribing Notes

Complete blood count should be monitored prior to the start of IBRANCE (Palbociclib) therapy and at the beginning of each cycle, as well as on Day 14 of the first 2 cycles, and as clinically indicated.

Take with food at about the same time each day. Swallow whole with a glass of water. Avoid grapefruit, grapefruit juice and any products containing grapefruit.

Allocated by:

Confirmed by:

Authorised by:

Checked by: (Pharmacist)

Date:

Date:

Date:

Date:

Parenteral

Intrathecal

Oral

1

0

1

Patient Details

Forename	Surname		Protocol	PALBOCICLIB										SA (m²)		
			Course Name	Palbociclib										Height (m)		
DOB	Patient NO		Local No.		NHS No								Weight (kg)			
Consultant			Ward		Diagnosis		Carcinoma of Breast									
Address																

Record drug allergies or sensitivities

				Time	Date													
Drug & dose	PALBOCICLIB																	
Actual dose	125 mg		Duration	21 DAYS														
Route	PO		Start Date															
Frequency	OD		Start Day	1														
Quantity		Dispensed by																
Dispensed		Accuracy check																
Note																		